FDA
approval
· 2022-03-29
FDA Approved: CABENUVA — Supplemental Application (ViiV Healthcare Company)
Summary
The FDA approved a supplemental application for CABENUVA (cabotegravir and rilpivirine), an injectable HIV treatment from ViiV Healthcare Company.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for CABENUVA (CABOTEGRAVIR AND RILPIVIRINE)